CAMBRIDGE, Mass., July 6, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the JMP Securities Healthcare Conference in New York City. Mark Fitzpatrick, CFO of Aegerion, is scheduled to present on Friday, July 13, 2012 at 11:30 a.m. ET.
The presentation will be webcast live and may be accessed for 90 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is committed to changing the way rare, life-threatening disorders are treated. We are an emerging biopharmaceutical company focused on the development and commercialization of novel, breakthrough therapeutics to treat debilitating and often fatal rare diseases. Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific and clinical excellence.